Article Details

VSY Biotechnology's Reviscon Mono 2% Receives Health Canada Approval for Osteoarthritis

Retrieved on: 2024-03-19 20:11:34

Tags for this article:

Click the tags to see associated articles and topics

VSY Biotechnology's Reviscon Mono 2% Receives Health Canada Approval for Osteoarthritis. View article details on hiswai:

Excerpt

VSY Biotechnology announced Health Canada's approval of Reviscon Mono 2% (2.4 ml), a one-time injectable solution for osteoarthritis pain and ...

Article found on: fox40.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo